Clinical Trial Update: Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) [Phase 2]

View source ↗

Summary

Phase 2 trial results assess the efficacy and safety of HyQvia (immunoglobulin 10% with recombinant hyaluronidase) in patients with Multifocal Motor Neuropathy.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multifocal Motor Neuropathy

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Sponsor: Johannes Jakobsen | Conditions: Multifocal Motor Neuropathy | Phase 2 | Status: COMPLETED